GENOCEA BIOSCIENCES, INC.
Profile
Company Names
GENOCEA BIOSCIENCES, INC.
Addresses
100 ACORN PARK DRIVE, CAMBRIDGE, MA 02140
CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA 02140
100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA 02140
161 FIRST STREET, SUITE 2C, CAMBRIDGE, MA 02139
Phone Numbers
617-876-8191
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY, PHARMACEUTICALS
Year Incorporated:
2006
State Incorporated:
DELAWARE
Total Amount Raised:
$153,574,777.00
Number of Funding Rounds:
5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2020-07-24
$75,508,015.00
$79,877,762.00
$4,369,747.00
Equity
4
2019-02-14
$12,066,763.00
$15,002,599.00
$2,935,836.00
Equity
3
2013-09-30
$400,000.00
$400,000.00
$0.00
2
2012-09-28
$30,500,000.00
$30,500,000.00
$0.00
Equity
1
2010-12-17
$35,099,999.00
$35,099,999.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
ALI
BEHBAHANI
DIRECTOR
ROTATION MEDICAL INC
| DENALI MEDICAL II, INC.
| MINERVA SURGICAL INC
| PROSPEX MEDICAL III, INC.
| OCULEVE, INC.
| CVRX INC
| IVANTIS, INC.
| ADAPTIMMUNE LTD
| CARDIONOMIC, INC.
| CVRX, INC.
| SOLACE THERAPEUTICS INC
| CRISPR THERAPEUTICS AG
| OYSTER POINT PHARMA, INC.
| GENOCEA BIOSCIENCES, INC.
| BLACK DIAMOND THERAPEUTICS, INC.
| SPYGLASS OPHTHALMICS, INC.
| ARCELLX, INC.
| NKARTA, INC.
| NEA BH SPV, L.P.
| NEA BH SPV II, L.P.
| MONTE ROSA THERAPEUTICS, INC.
| 858 THERAPEUTICS, INC.
| NEW ENTERPRISE ASSOCIATES 18, L.P.
| NEA 18 VENTURE GROWTH EQUITY, L.P.
| FIRSTLIGHT BIO, INC.
| NEXO THERAPEUTICS, INC.
| LAUNCHPAD THERAPEUTICS, INC.
| NEA SH SPV, L.P.
| SPYGLASSPHARMA, INC.
| NEA RP SPV, L.P.
| NEA CH SPV, L.P.
| NEA TS 2024 SPV, L.P.
| NEA SECONDARY OPPORTUNITY FUND, L.P.
| TUNE THERAPEUTICS, INC.
KEVIN
BITTERMAN
DIRECTOR
PARASOL THERAPEUTICS INC
| TARIS BIOMEDICAL INC
| BIOLEX THERAPEUTICS, INC.
| FOLLICA, INC
| VISTERRA, INC.
| KALA PHARMACEUTICALS, INC.
| GENOCEA BIOSCIENCES, INC.
| NEURONETICS, INC.
| DIRECT VET MARKETING, INC.
| EDITAS MEDICINE, INC.
| MORPHIC HOLDING, LLC
| ATLAS VENTURE FUND XI, L.P.
| NAVITOR PHARMACEUTICALS, INC.
| AKERO THERAPEUTICS, INC.
| ATLAS VENTURE OPPORTUNITY FUND I, L.P.
| ATLAS VENTURE FUND XII, L.P.
| KINASET THERAPEUTICS, INC.
| ATLAS VENTURE OPPORTUNITY FUND II, L.P.
| ATLAS VENTURE FUND XIII, L.P.
| JUDO BIO INC.
| CHROMA MEDICINE, INC.
| REMIX THERAPEUTICS, INC.
| GRO BIOSCIENCES INC.
| ATLAS VENTURE FUND XIV, L.P.
| RENASANT BIO, INC.
| ATLAS VENTURE OPPORTUNITY FUND ILL, L.P.
KATRINE
BOSLEY
DIRECTOR
LEON
CHEN
DIRECTOR
TIFFS TREATS HOLDINGS INC
| PARTSCHANNEL INVESTORS, INC.
| TIFF-S TREATS HOUSTON LTD.
| TIFF-S TREATS ATX 2 LTD.
| GENOCEA BIOSCIENCES, INC.
| CRESCENDO BIOSCIENCE, INC.
| TIFF-S TREATS HOLDINGS, INC.
| E-SCAPE BIO, INC.
| RFXCEL CORP
| LOGICBIO THERAPEUTICS, INC.
| FOG PHARMACEUTICALS, INC.
| NATURAL PARTNERS, INC
| NURIX THERAPEUTICS, INC.
| TIFF-S TREATS RALEIGH LTD.
| TIFF-S TREATS GP OKLAHOMA, LLC
| TIFF-S TREATS OKLAHOMA LTD.
| TIFF-S TREATS TAMPA, LTD.
| TIFF-S TREATS DENVER LTD.
| EIKON THERAPEUTICS, INC.
| SERANOVA BIO, INC.
| PLEXIUM, INC.
WILLIAM
CLARK
EXECUTIVE OFFICER, DIRECTOR
BRAZIL POTASH CORP.
| DELTEK, INC
| GENOCEA BIOSCIENCES, INC.
| MICROANGEL FUND I LLC
| MICROANGEL STARTUP FUND I LLC
| MICROANGEL FUND V LLC
| MICROANGEL FUND II LLC
| MICROANGEL FUND III LLC
| MICROANGEL INCUBATOR FUND I LLC
| MICROANGEL SMASH FUND I LLC
| MICROVENTURE MARKETPLACE INC.
| MICROANGEL STARTUP FUND VIII
| MICROANGEL EM FUND I
| MICROANGEL GRAPHICLY FUND I LLC
| MV STARTUP FUND I LLC SERIES 3
| SPINDLE, INC.
| MV VC FUND II, LLC
| DIAMOND KINETICS, INC.
| MV LIQUIDITY FUND XXIV LLC
| MV LIQUIDITY FUND XXV LLC
| MV STARTUP FUND XXIII LLC
| MV VENTURE FUND VI LLC
| MV STARTUP FUND XXIV LLC
| MV STARTUP FUND XXVI LLC
| SPARTAN FUND I LLC
| MV VC FUND VI LLC
| MV LIQUIDITY FUND XXIX LLC
| SAVI TECHNOLOGY, INC.
| MV LIQUIDITY FUND XXXII LLC
| MV VENTURE FUND VIII LLC
| MV STARTUP FUND XXIX LLC
| MV STARTUP FUND XXX LLC
| MV VC FUND VIII LLC
| MV VC FUND V LLC
| MV LIQUIDITY FUND XXVIII LLC
| JOYBOX STUDIOS, INC.
| WEESCHOOL, INC.
| ARSANIS, INC.
| GREY, INC.
| ROOBRIK, INC.
| JAW VENTURES, LLC
| ROMAN 413 INC.
| PARAMETRIX GROUP HOLDINGS, INC.
| IBIO, INC.
| UMA VENTURES SPV 0 LP
| UMA VENTURES I LP
| PIXION BATTERIES INC.
| DROVER VENTURES FUND I, LLC
THOMAS
DAVIS
EXECUTIVE OFFICER
SIMEON
GEORGE
DIRECTOR
SEMPRUS BIOSCIENCES CORP
| GENOCEA BIOSCIENCES, INC.
| HTG MOLECULAR DIAGNOSTICS INC
| AUXOGYN INC
| EFFECTOR THERAPEUTICS, INC.
| HTG MOLECULAR DIAGNOSTICS, INC
| AUXOGYN, INC.
| PRINCIPIA BIOPHARMA INC.
| PROGYNY, INC.
| TP THERAPEUTICS, INC.
| CRISPR THERAPEUTICS AG
| SR ONE CO-INVEST I, LLC
| SIMCHA THERAPEUTICS HOLDING COMPANY, LLC
| ADARX PHARMACEUTICALS, INC.
| SR ONE CAPITAL FUND II-B, LP
| SR ONE CAPITAL FUND II-A, LP
| AVENZO THERAPEUTICS, INC.
| REZO THERAPEUTICS, INC.
| SR ONE CAPITAL FUND III, LP
MICHAEL
HIGGINS
DIRECTOR
STEPHEN
HOFFMAN
DIRECTOR
STEVE
HOFFMAN
DIRECTOR
HOWARD
MAYER
DIRECTOR
ROBERT
PAULL
DIRECTOR
GEORGE
SIBER
DIRECTOR
ASISH
XAVIER
DIRECTOR
CELLADON CORP
| AQUINOX PHARMACEUTICALS (USA) INC
| AQUINOX PHARMACEUTICALS INC
| ISCIENCE INTERVENTIONAL CORP
| ISCIENCE INTERVENTIONAL CORP
| CATALYST BIOSCIENCES INC
| GENOCEA BIOSCIENCES, INC.
| ALDEXA THERAPEUTICS, INC.
| E-SCAPE BIO, INC.
| LODO THERAPEUTICS CORP
| PETRA PHARMA CORP
| APOGEN BIOTECHNOLOGIES, INC.
| RODEO THERAPEUTICS CORP
| PRONIRAS CORP
| MAGNOLIA NEUROSCIENCES CORP
| VIACYTE INC.
| ADICET BIO, INC.
| ESCAPE BIO, INC.
| IMMPACT BIO USA INC.
| PAIGE.AI, INC.
| SONOTHERA, INC.
| BRIGHT PEAK THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2020-07-24
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2019-02-14
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
